On May 7, 2025, the American College of Rheumatology (ACR) released the full guideline for diagnosing, monitoring, and treating lupus nephritis (LN), which appeared in Arthritis & Rheumatology.

WASHINGTON — Glucagon-like peptide 1 receptor agonist (GLP-1 RA) medications appear beneficial for people with systemic lupus erythematosus (SLE) and lupus nephritis, two new studies suggest.

Of course, patients with lupus nephritis lesions can change, so a patient can go from having just a class 1 or 2 to having a class 3 or 4 lesion. Patients can also go from having just pure class 5 ...

Doctors use different categories, called classes, to describe how severe lupus nephritis is. Your treatment plan will depend on your lupus nephritis class and your overall health. Treatment for lupus ...

Lupus nephritis is inflammation of the kidney that is caused by systemic lupus erythematosus (SLE). Also called lupus, SLE is an autoimmune disease. With lupus, the body's immune system targets ...

Lupus nephritis is a complication of systemic lupus erythematosus (SLE). It occurs when the immune system mistakenly attacks the kidneys, resulting in inflammation and organ damage. Because lupus ...

The glomerular pathology of recurrent lupus nephritis did not necessarily correlate with native disease, the investigators pointed out. Class 2 lupus nephritis was the most common disease state ...

Over the past dozen years, treatment approaches in lupus nephritis (LN ... analog (e.g., mycophenolate mofetil), depending on LN class Steroids should normally be tapered to no more than 5 ...

Those are the 2 initial screening tests—a urine test and a blood test. Once we get the results, and if there’s a suspicion of lupus nephritis, then we go on to what we call a kidney biopsy ...

It belongs to a class of medicines called calcineurin ... taken on an empty stomach either 1 hour before or 2 hours after a meal. For lupus nephritis, you will likely start at a dose of 23.7 ...

1.1 Voclosporin with mycophenolate mofetil is recommended, within its marketing authorisation, as an option for treating active class 3 to 5 (including mixed class 3 and 5, and 4 and 5) lupus ...